desipramine has been researched along with Diabetic Neuropathies in 13 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amitriptyline reduces the pain caused by peripheral-nerve disease, but treatment is often limited by side effects related to the drug's many pharmacologic actions." | 9.07 | Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. ( Dubner, R; Lynch, SA; Max, MB; Muir, J; Shoaf, SE; Smoller, B, 1992) |
| "Desipramine has the least anticholinergic and sedative effects of the first generation tricyclic antidepressants." | 6.67 | Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. ( Dubner, R; Gracely, RH; Kishore-Kumar, R; Max, MB; Meister, B; Schafer, SC; Smoller, B, 1991) |
| "Amitriptyline reduces the pain caused by peripheral-nerve disease, but treatment is often limited by side effects related to the drug's many pharmacologic actions." | 5.07 | Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. ( Dubner, R; Lynch, SA; Max, MB; Muir, J; Shoaf, SE; Smoller, B, 1992) |
| "Mianserin was given in the fixed dosage of 60 mg per day, whereas the dose of imipramine was adjusted to yield the optimal plasma concentration of imipramine plus desipramine of 400-600 nmol." | 2.67 | Lack of effect of mianserin on the symptoms of diabetic neuropathy. ( Beck-Nielsen, H; Brøsen, K; Gram, LF; Grodum, E; Sindrup, SH; Skjold, T; Tuxen, C, 1992) |
| "Desipramine has the least anticholinergic and sedative effects of the first generation tricyclic antidepressants." | 2.67 | Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. ( Dubner, R; Gracely, RH; Kishore-Kumar, R; Max, MB; Meister, B; Schafer, SC; Smoller, B, 1991) |
| "Paroxetine was given as a fixed dose of 40 mg/day, while the dose of imipramine was adjusted to yield optimal plasma levels of imipramine plus desipramine of 400-600 nM." | 2.67 | The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. ( Brøsen, K; Eshøj, O; Gram, LF; Mogensen, EF; Sindrup, SH, 1990) |
| "Desipramine levels were 130-910 nM, vs 860 and 880 nM." | 2.67 | Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. ( Beck-Nielsen, H; Brøsen, K; Gram, LF; Grodum, E; Sindrup, SH; Skjold, T, 1990) |
| "Desipramine has been shown in one small study to have efficacy equal to amitriptyline." | 2.40 | Tricyclic antidepressant use in diabetic neuropathy. ( Joss, JD, 1999) |
| "The imipramine doses were changed stepwise from doses yielding plasma concentrations of imipramine plus desipramine below 150 nM, up to doses yielding therapeutic drug levels of at least 300-500 nM." | 1.28 | Nonlinear kinetics of imipramine in low and medium plasma level ranges. ( Brøsen, K; Gram, LF; Sindrup, SH, 1990) |
| "Imipramine doses were individually adjusted until doses yielded plasma concentrations of imipramine plus desipramine that were well above 400 nmol/L or until all neuropathy symptoms had vanished." | 1.28 | Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms. ( Beck-Nielsen, H; Frøland, A; Gram, LF; Sindrup, SH; Skjold, T, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (76.92) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hearn, L | 1 |
| Moore, RA | 1 |
| Derry, S | 1 |
| Wiffen, PJ | 1 |
| Phillips, T | 1 |
| Bellows, BK | 1 |
| Nelson, RE | 1 |
| Oderda, GM | 1 |
| LaFleur, J | 1 |
| O'Connor, AB | 1 |
| Noyes, K | 1 |
| Holloway, RG | 1 |
| Mahoney, JE | 1 |
| Gray, SL | 1 |
| Carnes, M | 1 |
| Ido, Y | 1 |
| Chang, K | 1 |
| LeJeune, W | 1 |
| Tilton, RG | 1 |
| Monafo, WW | 1 |
| Williamson, JR | 1 |
| Joss, JD | 1 |
| Sindrup, SH | 5 |
| Tuxen, C | 1 |
| Gram, LF | 5 |
| Grodum, E | 2 |
| Skjold, T | 3 |
| Brøsen, K | 4 |
| Beck-Nielsen, H | 3 |
| Max, MB | 2 |
| Lynch, SA | 1 |
| Muir, J | 1 |
| Shoaf, SE | 1 |
| Smoller, B | 2 |
| Dubner, R | 2 |
| Kishore-Kumar, R | 1 |
| Schafer, SC | 1 |
| Meister, B | 1 |
| Gracely, RH | 1 |
| Eshøj, O | 1 |
| Mogensen, EF | 1 |
| Frøland, A | 1 |
2 reviews available for desipramine and Diabetic Neuropathies
| Article | Year |
|---|---|
Desipramine for neuropathic pain in adults.
Topics: Aged; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Chronic Pain; Clomipramine; Desip | 2014 |
Tricyclic antidepressant use in diabetic neuropathy.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Desipramine; Diabetic Neuropathies; Humans | 1999 |
5 trials available for desipramine and Diabetic Neuropathies
| Article | Year |
|---|---|
Lack of effect of mianserin on the symptoms of diabetic neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Desipramine; Diabetic Neuropathies; Double-Blind Meth | 1992 |
Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analgesics; Depression; Desipramine; Diabetic Neuropa | 1992 |
Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial.
Topics: Adult; Aged; Benztropine; Depression; Desipramine; Diabetic Neuropathies; Double-Blind Method; Emoti | 1991 |
The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms.
Topics: Depression; Desipramine; Diabetic Neuropathies; Humans; Imipramine; Nervous System; Osmolar Concentr | 1990 |
Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study.
Topics: Adult; Aged; Clomipramine; Desipramine; Diabetic Neuropathies; Double-Blind Method; Drug Evaluation; | 1990 |
6 other studies available for desipramine and Diabetic Neuropathies
| Article | Year |
|---|---|
Long-term cost-effectiveness of initiating treatment for painful diabetic neuropathy with pregabalin, duloxetine, gabapentin, or desipramine.
Topics: Amines; Analgesics; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids; Desipramine; Diabetic Neurop | 2016 |
A cost-utility comparison of four first-line medications in painful diabetic neuropathy.
Topics: Amines; Analgesics; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Cross-Sectional Studies | 2008 |
Prevention and treatment of the complications of diabetes mellitus.
Topics: Aged; Amitriptyline; Desipramine; Diabetic Neuropathies; Humans; Pain | 1995 |
Diabetes impairs sciatic nerve hyperemia induced by surgical trauma: implications for diabetic neuropathy.
Topics: Aldehyde Reductase; Animals; Desipramine; Diabetes Mellitus, Experimental; Diabetic Neuropathies; En | 1997 |
Nonlinear kinetics of imipramine in low and medium plasma level ranges.
Topics: Adult; Aged; Desipramine; Diabetic Neuropathies; Female; Half-Life; Homeostasis; Humans; Imipramine; | 1990 |
Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms.
Topics: Adult; Desipramine; Diabetic Neuropathies; Dose-Response Relationship, Drug; Female; Humans; Imipram | 1990 |